Kolexia
Heurgue Alexandra Gastro-entérologie
Heurgue Alexandra
Gastro-entérologie
Hôpital Robert-Debré Reims
Reims, France
127 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Hépatite Carcinomes Hépatite auto-immune Cirrhose biliaire Angiocholite Fibrose Tumeurs du foie Hypertension artérielle

Collaborateurs

Voir plus
Thiefin Gerard
Thiefin Gerard
Hôpital Robert-Debré Reims, Reims, France
Ollivier-Hourmand Isabelle
Ollivier-Hourmand Isabelle
Hôpital Côte de Nacre, Caen, France
Nguyen-Khac Eric
Nguyen-Khac Eric
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France
Bernard-Chabert Brigitte
Bernard-Chabert Brigitte
Hôpital Robert-Debré Reims, Reims, France

Industries

Voir plus
B3TSI
69 collaboration(s)
Dernière en 2023
A+A
40 collaboration(s)
Dernière en 2023
P\S\L Group Services
23 collaboration(s)
Dernière en 2022
Bayer
22 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PRO-SURFASA: Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis, a National Prospective Multicentre Study
Essai Clinique (Assistance publique – Hôpitaux de Paris)   11 mars 2024
ProPILARifax: A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin
Essai Clinique (CHU Besançon)   04 mars 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology   19 février 2024
Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination a Vascular Liver Disease Group (VALDIG) initiative.
Hepatology (Baltimore, Md.)   15 février 2024
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Essai Clinique (AstraZeneca)   09 janvier 2024
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study: Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   03 janvier 2024
SAFIR-ABC10: Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Essai Clinique (Taiho Oncology, Inc.)   15 novembre 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
The Lancet. Oncology   08 novembre 2023
147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Abstract Book of the ESMO Asia Congress 2023, 1-3 December 2023   01 novembre 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future oncology (London, England)   06 septembre 2023